alexa
Reach Us +44-176-4910199
Recent Advances In Biomarkers For Predicting Cancer Metastasis | 3549
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Recent advances in biomarkers for predicting cancer metastasis

2nd International Conference on Gastroenterology & Urology

Lui NG

AcceptedAbstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X.S1.019

Abstract
One major challenge of cancer treatment is metastatic disease development. The 5-year survival rate of cancer patients who have developed distant metastasis at diagnosis is extremely low, highlighting the importance of prediction and early detection of metastasis in cancer patients, which would definitely improve their prognosis as suitable patient therapeutic management and treatment strategy can be provided. Cancer cells from a primary site give rise to a metastatic tumor via a number of steps, requiring the involvement and alteration of a series of regulators. Hence, these regulators may serve as biomarkers for predicting metastasis. In this talk we will discuss some recent findings from our laboaratoy and other research groups on how these regulators are correlated with prediction of future metastasis.
Biography
Lui NG obstained his B.Sc. and M.Phil. from the Chinese University of Hong Kong and completed his Ph.D. from the University of Hong Kong Faculty of Medicine in 2012. He is currently a postdoctoral fellow at the same department, working on identification of novel regulators in cancer signaling pathways, screening of biomarkers for detecting cancer formation and progression and testing the efficacy of new drugs in combating cancers including hepatocellular carcinoma, colorectal cancer and leukemia.
Top